Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $789.62 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:09 PM 07/14/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT*) Snapshot

Open
$789.62
Previous Close
$789.62
Day High
$789.62
Day Low
$789.62
52 Week High
07/14/15 - $789.62
52 Week Low
10/2/14 - $551.50
Market Cap
1.2T
Average Volume 10 Days
35.1
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
07/13/15
P/E TM
--
Dividend
$0.93
Dividend Yield
1.76%
Current Stock Chart for ABBOTT LABORATORIES (ABT*)

abbott laboratories (ABT*) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices to treat vascular diseases. Abbott Laboratories also offers blood, continuous, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes under the FreeStyle brand; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

73,000 Employees
Last Reported Date: 07/22/15
Founded in 1888

abbott laboratories (ABT*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $2.0M
Executive Vice President of Ventures
Total Annual Compensation: $696.8K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $690.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Finance & Adminis...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

abbott laboratories (ABT*) Key Developments

Abbott Declares Quarterly Dividend, Payable on August 15, 2015; Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Full Year of 2015

On June 12, 2015, the board of directors of Abbott declared the company's quarterly dividend of $0.24 per share. Abbott's cash dividend is payable on Aug. 15, 2015, to shareholders of record at the close of business on July 15, 2015. The company announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $5,170 million, operating earnings of $729 million, earnings from continuing operations before taxes of $986 million, earnings from continuing operations of $786 million or $0.52 per diluted share, net earnings of $784 million or $0.52 per diluted share compared to the net sales of $5,057 million, operating earnings of $677 million, earnings from continuing operations before taxes of $658 million, earnings from continuing operations of $425 million or $0.28 per diluted share, net earnings of $466 million or $0.30 per diluted share for the same quarter a year ago. For the year to date, the company reported net sales of $10,067 million, operating earnings of $1,339 million, earnings from continuing operations before taxes of $1,639 million, earnings from continuing operations of $1,315 million of $0.87 per diluted share, net earnings of $3,076 million of $2.03 per diluted share compared to the net sales of $9,812 million, operating earnings of $1,042 million, earnings from continuing operations before taxes of $999 million, earnings from continuing operations of $649 million of $0.42 per diluted share, net earnings of $841 million of $0.55 per diluted share for the same period a year ago. The company reaffirmed earnings guidance for the full year of 2015. The company expects range for earnings per share from continuing operations, excluding specified items, remains unchanged at $2.10 to $2.20, representing strong growth at the mid-point of the guidance range. The company forecasts net specified items related to continuing operations for the full year 2015 of approximately $0.60 per share. Specified items include intangible amortization expense, charges associated with cost reduction initiatives, and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock. Including net specified items, projected earnings per share from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) would be $1.50 to $1.60 for the full year 2015.

U.S. Food and Drug Administration Approves the Launch of the iDesign Advanced WaveScan Studio System of Abbott

Abbott announced the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person's eyes. The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions 'all in one, three-second scan that can be used to precisely correct vision. Measuring Telescope Mirrors and Now Eyes: The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018.

Abbott to Invest USD 6.5 Million in Pharmaceutical Centre in Brazil

Abbott announced that the company plans to invest BRL 20 million (USD 6.5 million) to construct a pharmaceutical development centre in Brazil. The new Abbott centre will be located in Rio de Janeiro and its construction will begin in August. Abbott has not confirmed yet which products will be worked on at the unit, but has noted that the pharmaceutical centre will focus on cardiology, neurology, and gastroenterology medicines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT*:MM $789.62 MXN 0.00

ABT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,191 GBp -63.00
Danaher Corp $87.22 USD -0.56
Eli Lilly & Co $84.15 USD -0.57
Teva Pharmaceutical Industries Ltd $72.00 USD +10.15
Thermo Fisher Scientific Inc $137.02 USD -0.92
View Industry Companies
 

Industry Analysis

ABT*

Industry Average

Valuation ABT* Industry Range
Price/Earnings 32.6x
Price/Sales 3.7x
Price/Book 3.5x
Price/Cash Flow 14.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.